» Articles » PMID: 24262510

Fibroblast Growth Factor-23 and the Long-term Risk of Hospital-associated AKI Among Community-dwelling Older Individuals

Overview
Specialty Nephrology
Date 2013 Nov 23
PMID 24262510
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objectives: AKI occurs frequently in older persons. Elevated circulating fibroblast growth factor-23 (FGF-23), a known marker of impaired mineral metabolism, may also reflect tubular dysfunction and risk of AKI. This study evaluated FGF-23 as well as traditional markers of kidney disease, namely urine albumin-to-creatinine ratio (UACR) and creatinine-cystatin C estimated GFR (eGFRCrCyC), as risk factors for AKI in elderly individuals.

Design, Setting, Participants, & Measurements: Plasma FGF-23, UACR, and eGFRCrCyC were measured in 3241 community-dwelling elderly individuals in the Cardiovascular Health Study. Hospitalization for AKI was defined by International Classification of Diseases, Ninth Revision, Clinical Modification codes. Associations of each biomarker with AKI were evaluated using Cox proportional hazards models adjusted for demographics, cardiovascular risk factors, and biomarkers of kidney function.

Results: The mean participant age was 78 years; 60% of participants were women and 16% were African American. The median (interquartile range) values of biomarkers were as follows: FGF-23, 70 RU/ml (53, 99); UACR, 8.88 mg/g (4.71, 20.47); and eGFRCrCyC, 71 ml/min per 1.73 m(2) (59, 83). Hospitalized AKI occurred in 119 participants over 10.0 years of median follow-up. In fully adjusted analyses, compared with the lowest quartiles, the highest quartiles of FGF-23 (≥100 RU/ml) and UACR (≥20.9 mg/g) were associated with AKI (FGF-23: hazard ratio [HR], 1.99; 95% confidence interval [95% CI], 1.04 to 3.80; and UACR: HR, 3.35; 95% CI, 1.83 to 6.13). Compared with the highest quartile, the lowest quartile of eGFRCrCyC (<57 ml/min per 1.73 m(2)) was associated with AKI with an HR of 2.15 (95% CI, 1.21 to 3.82).

Conclusions: FGF-23 adjusted for albuminuria, cardiovascular disease risk factors, and baseline eGFR is independently associated with a higher risk of AKI hospitalizations in community-dwelling elderly individuals. Further studies to understand the nature of this association are warranted.

Citing Articles

Research progress of fibroblast growth factor 23 in acute kidney injury.

Zhang L, Qin W Pediatr Nephrol. 2022; 38(7):2013-2022.

PMID: 36416954 PMC: 10234887. DOI: 10.1007/s00467-022-05791-z.


Significance of serum FGF-23 for risk assessment of contrast-associated acute kidney injury and clinical outcomes in patients undergoing coronary angiography.

Huang S, Huang P, Leu H, Wu T, Chen J, Lin S PLoS One. 2021; 16(7):e0254835.

PMID: 34297744 PMC: 8301629. DOI: 10.1371/journal.pone.0254835.


25-hydroxyvitamin D, Fibroblast Growth Factor 23, and Risk of Acute Kidney Injury Over 20 Years of Follow-Up.

Ishigami J, Grams M, Michos E, Lutsey P, Matsushita K Kidney Int Rep. 2021; 6(5):1299-1308.

PMID: 34013108 PMC: 8116771. DOI: 10.1016/j.ekir.2021.02.009.


FGF23 ameliorates ischemia-reperfusion induced acute kidney injury via modulation of endothelial progenitor cells: targeting SDF-1/CXCR4 signaling.

Chang H, Peng K, Chan C, Sun C, Chen Y, Chang H Cell Death Dis. 2021; 12(5):409.

PMID: 33866326 PMC: 8053200. DOI: 10.1038/s41419-021-03693-w.


Fibroblast Growth Factor 23 and Mortality Among Prevalent Hemodialysis Patients in the Japan Dialysis Outcomes and Practice Patterns Study.

Komaba H, Fuller D, Taniguchi M, Yamamoto S, Nomura T, Zhao J Kidney Int Rep. 2020; 5(11):1956-1964.

PMID: 33163716 PMC: 7609896. DOI: 10.1016/j.ekir.2020.08.013.


References
1.
Vaidya V, Waikar S, Ferguson M, Collings F, Sunderland K, Gioules C . Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. Clin Transl Sci. 2009; 1(3):200-8. PMC: 2638059. DOI: 10.1111/j.1752-8062.2008.00053.x. View

2.
Isakova T, Xie H, Yang W, Xie D, Anderson A, Scialla J . Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011; 305(23):2432-9. PMC: 3124770. DOI: 10.1001/jama.2011.826. View

3.
Leaf D, Wolf M, Waikar S, Chase H, Christov M, Cremers S . FGF-23 levels in patients with AKI and risk of adverse outcomes. Clin J Am Soc Nephrol. 2012; 7(8):1217-23. PMC: 3408118. DOI: 10.2215/CJN.00550112. View

4.
Schoppet M, Hofbauer L, Brinskelle-Schmal N, Varennes A, Goudable J, Richard M . Serum level of the phosphaturic factor FGF23 is associated with abdominal aortic calcification in men: the STRAMBO study. J Clin Endocrinol Metab. 2012; 97(4):E575-83. DOI: 10.1210/jc.2011-2836. View

5.
Grams M, Astor B, Bash L, Matsushita K, Wang Y, Coresh J . Albuminuria and estimated glomerular filtration rate independently associate with acute kidney injury. J Am Soc Nephrol. 2010; 21(10):1757-64. PMC: 3013549. DOI: 10.1681/ASN.2010010128. View